Efficacy and Safety of Adjunctive Lumateperone 42 mg in Major Depressive Disorder: A Pooled Analysis of Demographic and Clinical Subgroups from 2 Phase 3 Randomized Placebo-Controlled Trials

Mar 29, 2026 — 1:00 PM - 1:05 PM
Exhibition Hall

Depressive Disorders
Presenter:
Willie Earley (United States)

Session Type

E-Poster Presentation